Pauline Brevet
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Pauline Brevet has a total of 92 co-authors. Here are the top co-authors by number of shared publications:
- Olivier Vittecoq
Department of Rheumatology & CIC-CRB 1404, Univ Rouen Normandie, Normandie Univ, CHU Rouen, CHU de Rouen, 1 rue de Germont, 76031 Rouen cedex, Rouen, F-76000, France
6 shared publications - Baptiste Gerard
Department of Rheumatology, Rouen University Hospital, F-76000 Rouen, France
5 shared publications Olivier Vittecoq
5 shared publicationsThierry Lequerré
Univ Rouen Normandie, Inserm, PANTHER UMR 1234, CHU Rouen, Department of Rheumatology & CIC-CRB 1404, 76000 Rouen, France
4 shared publications- Alexandre Curie
Internal Medicine department, Rouen University Hospital Center, 1, rue de Germont, 76031 Rouen, France
3 shared publications - Didier Alcaix
Rheumatology department, Le Havre Monod Hospital, 29, avenue Pierre-Mendes France, 76290 Montivilliers, France
3 shared publications
Latest Publications
- Open Access
- 19 June 2026
- Published by Springer Nature in BMC Musculoskeletal Disorders
- Vol. 27 (1)
Women with spondyloarthritis occurring in the peripartum period develop a singular phenotype
Background: Spondyloarthritis (SpA) has specific features in women and may be triggered by parturition. The peripartum period is marked by musculoskeletal remodelling and IL-17 secreting cell activation to enable childbirth. We therefore hypothesized that peripartum SpA might predominantly involve the entheses and be less dependent on HLA-B27 and TNFα. Methods: We conducted a retrospective, observational, case-control study using the Rouen University Hospital’s clinical data warehouse. Delivery dates and symptom onset were available for 154 women with SpA. Characteristics were compared between cases (with peripartum SpA) and controls. Results: We identified 58 cases and 96 controls. HLA-B27 (37.3% vs. 52.3%, p-value: 0.04), anterior chest syndrome (74.1% vs. 54.7%, p-value: 0.012 and psoriasis (37.9% vs. 16.8%, p-value: 0.004 were significantly associated with peripartum SpA. Lower rates of biological inflammatory syndrome at TNFα inhibitor introduction, (22.2% vs. 48.1%, p-value: 0.003), of radiographic sacroiliac damage (4% vs. 18.6%, p-value: 0.012 and of MRI sacroiliitis (30.6% vs. 47.4%, p-value: 0.046 were observed in women with peripartum SpA. Also, a lower retention rate of TNFα inhibitors was observed in women with peripartum SpA, 45.6% at 12 months, versus 71.2% controls (Odd ratio: 2.56 [95% CI: 1.34–4.95]). Multivariate survival analysis found a hazard ratio for TNFα inhibitor discontinuation of 2.43 (95% CI: 1.62–3.65) within the first two years of treatment. Conclusions: Our study highlights a distinct phenotype of peripartum SpA, and a lower retention rate of TNFα inhibitors suggesting a worse response to these class of bDMARD. Trial registration: As we conducted a retrospective study without health care intervention, no prospective registration was done.
- 19 June 2026
- Published by Springer Nature in BMC Musculoskeletal Disorders
- Vol. 27 (1)
Open AccessWomen with spondyloarthritis occurring in the peripartum period develop a singular phenotype
Background: Spondyloarthritis (SpA) has specific features in women and may be triggered by parturition. The peripartum period is marked by musculoskeletal remodelling and IL-17 secreting cell activation to enable childbirth. We therefore hypothesized that peripartum SpA might predominantly involve the entheses and be less dependent on HLA-B27 and TNFα. Methods: We conducted a retrospective, observational, case-control study using the Rouen University Hospital’s clinical data warehouse. Delivery dates and symptom onset were available for 154 women with SpA. Characteristics were compared between cases (with peripartum SpA) and controls. Results: We identified 58 cases and 96 controls. HLA-B27 (37.3% vs. 52.3%, p-value: 0.04), anterior chest syndrome (74.1% vs. 54.7%, p-value: 0.012 and psoriasis (37.9% vs. 16.8%, p-value: 0.004 were significantly associated with peripartum SpA. Lower rates of biological inflammatory syndrome at TNFα inhibitor introduction, (22.2% vs. 48.1%, p-value: 0.003), of radiographic sacroiliac damage (4% vs. 18.6%, p-value: 0.012 and of MRI sacroiliitis (30.6% vs. 47.4%, p-value: 0.046 were observed in women with peripartum SpA. Also, a lower retention rate of TNFα inhibitors was observed in women with peripartum SpA, 45.6% at 12 months, versus 71.2% controls (Odd ratio: 2.56 [95% CI: 1.34–4.95]). Multivariate survival analysis found a hazard ratio for TNFα inhibitor discontinuation of 2.43 (95% CI: 1.62–3.65) within the first two years of treatment. Conclusions: Our study highlights a distinct phenotype of peripartum SpA, and a lower retention rate of TNFα inhibitors suggesting a worse response to these class of bDMARD. Trial registration: As we conducted a retrospective study without health care intervention, no prospective registration was done.
- Open Access
- 20 March 2026
- Published by Elsevier in Orthopaedics & Traumatology: Surgery & Research
- p. 104689
Early postoperative activity tracking shows excessive ambulation and poor adherence to recommendations after hallux valgus surgery
- 20 March 2026
- Published by Elsevier in Orthopaedics & Traumatology: Surgery & Research
- p. 104689
Open AccessEarly postoperative activity tracking shows excessive ambulation and poor adherence to recommendations after hallux valgus surgery
- 3 May 2025
- Published by Elsevier in Joint Bone Spine
- Vol. 92 (5) , 105918
Evaluation by modern imaging of anterior chest wall involvement in axial spondyloarthritis with or without chest complaint
- 3 May 2025
- Published by Elsevier in Joint Bone Spine
- Vol. 92 (5) , 105918
Evaluation by modern imaging of anterior chest wall involvement in axial spondyloarthritis with or without chest complaint
- 25 February 2025
- Published by Elsevier in Joint Bone Spine
- Vol. 92 (5) , 105869
Could the anti-modified protein antibody concept help better define seronegative rheumatoid arthritis?
- 25 February 2025
- Published by Elsevier in Joint Bone Spine
- Vol. 92 (5) , 105869
Could the anti-modified protein antibody concept help better define seronegative rheumatoid arthritis?
- Open Access
On difficulties to define prognostic factors for clinical practice in rheumatoid arthritis
In rheumatoid arthritis (RA), the identification of prognostic factors (PF) capable of predicting disease outcome, response to treatment or success of dose reduction is an important issue, as these factors are intended to serve as a basis for decision-making. The task is complex from the outset, as the definition of disease prognosis or therapeutic prognosis is not uniquevocal. The heterogeneity of the definitions used partly explains the failure to identify PF that can be applied at an individual level. But other factors also contribute. First, the scope of the disease studied is too broad, including nosologically different entities. Second, potential PF are only measured at a single point of time, whereas changes over a period of time should be taken into account to a greater extent, not forgetting the potential impact of the treatment received during this period. Beyond these limiting factors, one of the main obstacles to the identification of PF is probably the fact that the phase of the disease is not sufficiently taken into account. Predicting the disease outcome when it is well established is a more complex challenge than when it is just beginning, as many factors are likely to interfere. The same applies to therapeutic PF, which should be determined according to disease duration. Difficulties also arise from the approaches used, which are often restricted to a single field of interest whereas they should be much more integrative and call on new large-scale data analysis tools with a view to precision medicine. In RA, prognosis can be defined at two levels: disease outcome, including joint damage and risk of extra-articular manifestations and/or complications, and treatment outcome, including response to therapy, risk of adverse effects and drug-free remission.
Open AccessOn difficulties to define prognostic factors for clinical practice in rheumatoid arthritis
In rheumatoid arthritis (RA), the identification of prognostic factors (PF) capable of predicting disease outcome, response to treatment or success of dose reduction is an important issue, as these factors are intended to serve as a basis for decision-making. The task is complex from the outset, as the definition of disease prognosis or therapeutic prognosis is not uniquevocal. The heterogeneity of the definitions used partly explains the failure to identify PF that can be applied at an individual level. But other factors also contribute. First, the scope of the disease studied is too broad, including nosologically different entities. Second, potential PF are only measured at a single point of time, whereas changes over a period of time should be taken into account to a greater extent, not forgetting the potential impact of the treatment received during this period. Beyond these limiting factors, one of the main obstacles to the identification of PF is probably the fact that the phase of the disease is not sufficiently taken into account. Predicting the disease outcome when it is well established is a more complex challenge than when it is just beginning, as many factors are likely to interfere. The same applies to therapeutic PF, which should be determined according to disease duration. Difficulties also arise from the approaches used, which are often restricted to a single field of interest whereas they should be much more integrative and call on new large-scale data analysis tools with a view to precision medicine. In RA, prognosis can be defined at two levels: disease outcome, including joint damage and risk of extra-articular manifestations and/or complications, and treatment outcome, including response to therapy, risk of adverse effects and drug-free remission.
- 29 July 2024
- Published by Elsevier in Joint Bone Spine
- Vol. 91 (5) , 105764
A pilot study of refractory enthesitis treated with CO2 laser in spondyloarthritis and psoriatic arthritis
- 29 July 2024
- Published by Elsevier in Joint Bone Spine
- Vol. 91 (5) , 105764
A pilot study of refractory enthesitis treated with CO2 laser in spondyloarthritis and psoriatic arthritis
- Open Access
- 23 July 2024
- Published by MDPI AG in Healthcare
- Vol. 12 (15) , 1463
Impact of the Clinical Pharmacist in Rheumatology Practice: A Systematic Review
This is a systematic literature review on the impact of pharmacists in rheumatology, conducted using the PubMed®, CINAHL®, Cochrane Library®, and Web of science® databases and using the PRISMA 2020 checklist. This review was conducted from 2000 to June 2024. A quality analysis was performed. The selection of articles, as well as all analyses, including quality analyses, were conducted by a pair of pharmacists with experience in rheumatology, and included 24 articles. This study highlights the growth of clinical pharmacy activities in rheumatology and the positive influence of clinical pharmacists on patient care. The implementation of such initiatives has the potential to improve medication adherence, reduce medication-related risks, and optimize associated healthcare costs. All these pharmaceutical interventions aim to make the patient care journey smoother and safer. Additionally, the diversity of available pharmaceutical services caters to the varied needs of rheumatology. Furthermore, outpatient clinical pharmacy is also explored in this field and garners interest from patients. The vast majority of studies demonstrate significant improvement in patient care with promising performance outcomes when pharmacists are involved. This review highlights the diverse range of interventions by clinical pharmacists in rheumatology, which is very promising. However, to better assess the benefits of clinical pharmacists, this activity needs further development and evaluation through controlled and randomized clinical research programs.
- 23 July 2024
- Published by MDPI AG in Healthcare
- Vol. 12 (15) , 1463
Open AccessImpact of the Clinical Pharmacist in Rheumatology Practice: A Systematic Review
This is a systematic literature review on the impact of pharmacists in rheumatology, conducted using the PubMed®, CINAHL®, Cochrane Library®, and Web of science® databases and using the PRISMA 2020 checklist. This review was conducted from 2000 to June 2024. A quality analysis was performed. The selection of articles, as well as all analyses, including quality analyses, were conducted by a pair of pharmacists with experience in rheumatology, and included 24 articles. This study highlights the growth of clinical pharmacy activities in rheumatology and the positive influence of clinical pharmacists on patient care. The implementation of such initiatives has the potential to improve medication adherence, reduce medication-related risks, and optimize associated healthcare costs. All these pharmaceutical interventions aim to make the patient care journey smoother and safer. Additionally, the diversity of available pharmaceutical services caters to the varied needs of rheumatology. Furthermore, outpatient clinical pharmacy is also explored in this field and garners interest from patients. The vast majority of studies demonstrate significant improvement in patient care with promising performance outcomes when pharmacists are involved. This review highlights the diverse range of interventions by clinical pharmacists in rheumatology, which is very promising. However, to better assess the benefits of clinical pharmacists, this activity needs further development and evaluation through controlled and randomized clinical research programs.
- Open Access
- 3 June 2024
- Published by MDPI AG in Healthcare
- Vol. 12 (11) , 1138
An Overview of Opioid Prescription Patterns among Non-Opioid Users Following Emergency Department Admission
The evolving landscape of opioid prescription practices necessitates a comprehensive understanding of emerging patterns, particularly among new opioid users discharged from emergency departments. This study delves into the intricate realm of opioid utilization by elucidating the prevalence of their prescriptions. A retrospective analysis of electronic health records was conducted, including a cohort of 71 patients who received opioid prescriptions upon discharge from emergency departments from 1 January 2022 to 30 June 2022. Demographic characteristics and prescription details were systematically examined. This study illuminates tramadol’s prominence, with 84% of prescriptions and a Defined Daily Dose (DDD) morphine equivalent of 60 mg, as the primary choice as a new opioid, a finding that draws attention due to the closely aligned dosages with morphine equivalents. This discovery prompts a critical reassessment of tramadol’s therapeutic role, considering its multifaceted nature encompassing serotonergic effects and heightened fall risks. This study advocates for a nuanced and vigilant approach to tramadol prescription, cognizant of its potential risks and therapeutic implications, and highlights the imperative of optimizing data quality and traceability within electronic health records to enhance patient care and facilitate future research endeavors.
- 3 June 2024
- Published by MDPI AG in Healthcare
- Vol. 12 (11) , 1138
Open AccessAn Overview of Opioid Prescription Patterns among Non-Opioid Users Following Emergency Department Admission
The evolving landscape of opioid prescription practices necessitates a comprehensive understanding of emerging patterns, particularly among new opioid users discharged from emergency departments. This study delves into the intricate realm of opioid utilization by elucidating the prevalence of their prescriptions. A retrospective analysis of electronic health records was conducted, including a cohort of 71 patients who received opioid prescriptions upon discharge from emergency departments from 1 January 2022 to 30 June 2022. Demographic characteristics and prescription details were systematically examined. This study illuminates tramadol’s prominence, with 84% of prescriptions and a Defined Daily Dose (DDD) morphine equivalent of 60 mg, as the primary choice as a new opioid, a finding that draws attention due to the closely aligned dosages with morphine equivalents. This discovery prompts a critical reassessment of tramadol’s therapeutic role, considering its multifaceted nature encompassing serotonergic effects and heightened fall risks. This study advocates for a nuanced and vigilant approach to tramadol prescription, cognizant of its potential risks and therapeutic implications, and highlights the imperative of optimizing data quality and traceability within electronic health records to enhance patient care and facilitate future research endeavors.